“`html
HIV Prevention Pill Access Expands with FDA Approval of Long-Acting Injectable
Published: 2025/11/23 20:35:51
A new era in HIV prevention has begun with the Food and Drug Administration (FDA) approval of a long-acting injectable form of cabotegravir, marketed as Apretude. This approval, announced in December 2021, offers a significant choice to daily oral PrEP (pre-exposure prophylaxis) pills, potentially increasing access and adherence for individuals at risk of HIV infection. The expanded approval in 2024 now includes adolescents weighing at least 77 pounds. This growth is poised to reshape HIV prevention strategies and contribute to ending the HIV epidemic.
What is PrEP and Why is a Long-Acting Injectable Significant?
PrEP involves taking a daily pill to prevent HIV infection in people who are HIV-negative but at risk. While highly effective, daily adherence can be a challenge for some. Missing doses can reduce PrEP’s effectiveness. A long-acting injectable, administered every two months, eliminates the need for daily pills, addressing a major barrier to prevention.
How Does Apretude (Cabotegravir) Work?
Cabotegravir belongs to a class of drugs called integrase strand transfer inhibitors (INSTIs). It works by interfering with the virus’s ability to integrate its genetic material into the host cell’s DNA, preventing replication. Apretude is administered as two intramuscular injections in the buttocks,given one month apart for the initial period,followed by injections every two months thereafter. FDA Approval Details
Who is Apretude For?
Apretude is approved for adults and adolescents weighing at least 77 pounds who are at risk of contracting HIV-1. Risk factors include:
- Having a sexual partner who is HIV-positive.
- Having sex without consistently using condoms.
- Having a history of sexually transmitted infections (STIs).
- Injecting drugs.
Before starting Apretude, individuals must test negative for HIV-1. It is indeed not a substitute for safe sex practices.
Clinical Trial Results and Efficacy
The approval of Apretude is based on data from two clinical trials: HPTN 083 and HPTN 084. These trials demonstrated that cabotegravir was substantially more effective than daily oral PrEP in preventing HIV infection.
- HPTN 083: Showed a 69% reduction in HIV acquisition among men who have sex with men and transgender women compared to daily oral PrEP.
- HPTN 084: Demonstrated a significant reduction in HIV acquisition among women in sub-Saharan Africa.
Potential Side Effects and Considerations
Common side effects of Apretude include:
- Pain or swelling at the injection site
- Fever
- headache
- Muscle pain
- Nausea
serious side effects are rare but can occur. Individuals should discuss potential risks and benefits with their healthcare provider. It’s also important to note that Apretude does not protect against other sexually transmitted infections.
Access and Cost
access to Apretude might potentially be limited initially due to the need for specialized training for healthcare providers administering the injections. Cost is also a factor, even tho patient assistance programs and insurance coverage are expected to improve access over time. The CDC provides resources and guidance on prep access and affordability. CDC PrEP Resources
Key Takeaways
- Apretude offers a new, long-acting injectable option
Related reading